Trial Profile
Intracoronary Stenting and Angiographic Results: ORSIRO Stents Versus Xience PRIME Stents Assessed by Optical Coherence Tomography
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Oct 2022
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Everolimus
- Indications Coronary artery disease; Coronary artery restenosis; Coronary disorders; Myocardial ischaemia
- Focus Therapeutic Use
- Acronyms ORSIRO OCT
- 03 Aug 2017 Status changed from recruiting to completed.
- 01 Jul 2013 Planned End Date changed from 1 May 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov.
- 15 May 2012 New trial record